Key Developments: Alexion Pharmaceuticals Inc (ALXN.O)

ALXN.O on Nasdaq

180.37USD
27 Feb 2015
Change (% chg)

$-2.74 (-1.50%)
Prev Close
$183.11
Open
$183.08
Day's High
$183.99
Day's Low
$179.44
Volume
944,706
Avg. Vol
1,267,470
52-wk High
$203.30
52-wk Low
$136.37

Search Stocks

Latest Key Developments (Source: Significant Developments)

Alexion Pharmaceuticals appoints CEO
Thursday, 29 Jan 2015 06:30am EST 

Alexion Pharmaceuticals Inc:Appointed David L. Hallal as the Chief Executive Officer (CEO), effective April 1.Hallal currently serves as Alexion's Chief Operating Officer (COO) and is a Director of the Board. He will succeed Leonard Bell, M.D., Chairman and CEO, who will retire as CEO and continue to serve as Chairman of the Board.  Full Article

Alexion Pharmaceuticals Inc gives FY 2015 outlook below analysts' estimates
Thursday, 29 Jan 2015 06:27am EST 

Alexion Pharmaceuticals Inc:Expects FY 2015 worldwide net product sales are to be within a range of $2.55 to $2.6 billion.FY 2015 non-GAAP earnings per share to be $5.60 to $5.80.FY 2015 revenue of $2.73 billion, EPS of $5.91 - Thomson Reuters I/B/E/S.  Full Article

Alexion Pharmaceuticals Inc reaffirms FY 2014 guidance - Conference Call
Monday, 12 Jan 2015 01:30pm EST 

Alexion Pharmaceuticals Inc:Says financial guidance for FY 2014 remains unchanged with revenue growing at 38 pct and non-GAAP EPS growing at 56 pct.FY 2014 EPS of $5.20 - Thomson Reuters I/B/E/S.  Full Article

Alexion Pharmaceuticals Inc completes rolling BLA submission to U.S. FDA for Asfotase Alfa as treatment for patients with Hypophosphatasia
Tuesday, 30 Dec 2014 06:30am EST 

Alexion Pharmaceuticals Inc:Says completion of rolling submission of Biologics License Application (BLA) to U.S. (FDA) for asfotase alfa, an investigational, first-in-class enzyme replacement therapy for the treatment of hypophosphatasia (HPP).Says HPP is genetic, chronic and progressive ultra-rare metabolic disease that can lead to destruction and deformity of bones, profound muscle weakness, seizures, respiratory failure and premature death (1-5).  Full Article

Alexion Pharmaceuticals Inc announces $500 mln share repurchase program
Monday, 15 Dec 2014 06:30am EST 

Alexion Pharmaceuticals Inc:Says new share repurchase program of up to $500 mln.New share repurchase program will take effect upon completion of company's current program, which has about $22 mln remaining of its previously authorized $400 mln.  Full Article

Alexion Pharmaceuticals Inc's Soliris (eculizumab) Granted Orphan Drug Designation in Japan
Wednesday, 10 Dec 2014 04:15pm EST 

Alexion Pharmaceuticals Inc:Says that Soliris(eculizumab) has been granted orphan drug designation (ODD) by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myasthenia gravis (MG), a rare, debilitating neurologic disorder.In patients with MG, uncontrolled complement activation due to antibodies directed at the neuromuscular junction can ultimately lead to profound and debilitating weakness of various muscle groups throughout the body.This significant muscle weakness can impair patients' ability to walk, speak clearly, swallow and, in some cases, to breathe.  Full Article

Alexion Pharmaceuticals's Soliris receives orphan drug designation by Japan's Ministry of Health, Labour and Welfare
Tuesday, 25 Nov 2014 06:30am EST 

Alexion Pharmaceuticals Inc:Says it has been granted orphan drug designation by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with neuromyelitis optica, a life-threatening, ultra-rare neurologic disorder.In patients with NMO, chronic, uncontrolled complement activation results in severe damage to the central nervous system (CNS), predominantly impacting the optic nerve and spinal cord.  Full Article

Alexion Pharmaceuticals Inc raises FY 2014 guidance - Conference Call
Thursday, 23 Oct 2014 10:00am EDT 

Alexion Pharmaceuticals Inc:Raises FY 2014 revenue guidance to the higher rage to $2.220 billion to $2.225 billion.Raises FY 2014 guidance for non-GAAP EPS to the higher range of $5.15 to $5.20, reflecting ongoing financial discipline and the operational benefits of global structure.FY 2014 revenue of $2.201 billion and EPS of $5.02 - Thomson Reuters I/B/E/S.  Full Article

Alexion Pharmaceuticals Inc submits NDA in Japan for Asfotase Alfa as treatment for patients with Hypophosphatasia
Wednesday, 15 Oct 2014 06:30am EDT 

Alexion Pharmaceuticals Inc:Submitted New Drug Application (NDA) for asfotase alfa, an investigational, first-in-class targeted enzyme replacement therapy for treatment of hypophosphatasia (HPP), to Japan's Ministry of Health, Labour and Welfare (MHLW).HPP is genetic, chronic and progressive ultra-rare metabolic disease that can lead to destruction and deformity of bones, profound muscle weakness, seizures, respiratory failure and premature death (1-5).MHLW submission includes positive data from 71 patients with HPP (ranging from newborns to 66 years of age), including Japanese patients, enrolled in three pivotal prospective studies and their extensions, as well as a retrospective natural history study in infants.  Full Article

Alexion Pharmaceuticals Inc appoints new chairman
Thursday, 9 Oct 2014 06:30am EDT 

Alexion Pharmaceuticals Inc:Says Leonard Bell, M.D. has been appointed chairman of the board of directors.Bell, principal founder of Alexion, continues to serve as chief executive officer.  Full Article

UPDATE 1-Alexion Pharma quarterly adj profit beats, raises forecast again

Oct 23 - Alexion Pharmaceuticals Inc reported a better-than-expected adjusted quarterly profit on strong sales of its blood disorder drug Soliris and raised its full-year profit forecast for the fourth time this year.

Search Stocks